

Pharmacy BULLETIN BOARD

Industry Issue ■ Monday May 12, 2014.

UriSec® emollient creams and lotions are patient friendly formulations ideal for winter dryness and itchy skin.

Product	Sizes	Odan Code	Kohl & Frisch Code	McKesson Code	McMahon Code
UriSec® 10% Cream NPN 80005397	75 g	38075	32617	513085	26638401
	120 g	38045	32618	513341	26638301
UriSec 12% Lotion NPN 00514896	250 mL	230J	48909	115493	26623101
	120 g	220Q	46312	115444	26623201
UriSec® 22% Cream NPN 00396125	225 g	220C	-	153486	26537801
	454 g	220R	46309	848549	26632301
UriSec® 40 Cream NPN 80005531	15 g	45014	114939	003743	-
	30 g	45028	32606	799437	27127401
	100 g	45067	32616	799494	26640001

UriSec® products are prescribed by Dermatologists and Physicians and are used by both patients and hospitals across Canada.

To order, please contact your wholesaler or Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com



UriSec® is a registered trademark of Odan Laboratories Ltd.



OTTAWA: The Government of Canada has announced the creation of the Canadian Clinical Trials Coordinating Centre (CCTCC) – a collaborative effort of the Canadian Institutes of Health Research (CIHR), Canada's Research-Based Pharmaceutical Companies (Rx&D), and the merged organizations of the Association of Canadian Academic Healthcare Organizations and the Canadian Healthcare Association (ACAHO/CHA). The CCTCC will be housed at the offices of the Health Charities Coalition of Canada, in Ottawa.

FROM THE NEWSWIRE

MISSISSAUGA, ON: Roche announced that Health Canada has approved a subcutaneous (SC) formulation of ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have inadequate response to one or more disease modifying anti-rheumatic drugs (DMARDs) and/or tumour necrosis factor (TNF) antagonists. Like the intravenous (IV) formulation, the SC formulation can be used both as a single-agent therapy, or monotherapy, and in combination with methotrexate or other non-biologic DMARDs. The ACTEMRA pre-filled syringe (PFS) injection formulation will be available in Canada in June.

MISSISSAUGA, ON: Women with HER2-positive metastatic breast cancer in British Columbia will now be able to access a new treatment option through the BC Cancer Agency. The BC Cancer Systemic Therapy Program has approved the addition of KADCYLA® (trastuzumab emtansine) to be added to the BCCA Drug Benefit Listing. KADCYLA has been approved as second line treatment for patients with HER2-positive, unresectable locally advanced or metastatic breast cancer, who have received prior treatment with HERCEPTIN® (trastuzumab) plus chemotherapy in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with trastuzumab plus chemotherapy.

NEW YORK, NY and LAVAL, QC: Aven Therapeutics, the global private equity company focused on accelerated development of breakthrough therapeutic drugs and BELLUS Health Inc., a drug development company focused on rare diseases, has announced that Aven has entered into a license agreement with the Icahn School of Medicine at Mount Sinai in New York, under which Aven obtains rights to develop KIIACTA™ (eprodinate) as a treatment for chronic sarcoidosis.

OTTAWA: The Mental Health Commission of Canada (MHCC) has launched #308conversations, a national grassroots suicide prevention campaign that invites each of Canada's 308 Members of Parliament (MPs) to lead a conversation with their constituents about suicide prevention.

To include your communication in the next issue, please contact: Health Response

T: 416-863-5403 | F: 416-863-9620 | hrc@healthresponse.ca

Next Issue: Monday May 26th, 2014

Deadline: Thursday May 22nd, 2014